nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—TNF—coronary artery disease	0.132	0.447	CbGaD
Thalidomide—CYP2C19—coronary artery disease	0.1	0.341	CbGaD
Thalidomide—PTGS2—coronary artery disease	0.0626	0.212	CbGaD
Thalidomide—PTGS2—Acetylsalicylic acid—coronary artery disease	0.0208	0.057	CbGbCtD
Thalidomide—PTGS1—Acetylsalicylic acid—coronary artery disease	0.0176	0.0481	CbGbCtD
Thalidomide—CYP3A5—Clopidogrel—coronary artery disease	0.0168	0.046	CbGbCtD
Thalidomide—CYP2C9—Fenofibrate—coronary artery disease	0.0163	0.0445	CbGbCtD
Thalidomide—CYP2C19—Gemfibrozil—coronary artery disease	0.0156	0.0428	CbGbCtD
Thalidomide—CYP3A5—Eplerenone—coronary artery disease	0.0156	0.0428	CbGbCtD
Thalidomide—CYP1A2—Gemfibrozil—coronary artery disease	0.0144	0.0395	CbGbCtD
Thalidomide—CYP2C19—Clopidogrel—coronary artery disease	0.0136	0.0371	CbGbCtD
Thalidomide—CYP2C9—Gemfibrozil—coronary artery disease	0.013	0.0356	CbGbCtD
Thalidomide—CYP1A2—Clopidogrel—coronary artery disease	0.0125	0.0342	CbGbCtD
Thalidomide—CYP2C19—Telmisartan—coronary artery disease	0.0119	0.0324	CbGbCtD
Thalidomide—CYP2C9—Clopidogrel—coronary artery disease	0.0113	0.0309	CbGbCtD
Thalidomide—CYP3A5—Rosuvastatin—coronary artery disease	0.0108	0.0296	CbGbCtD
Thalidomide—CYP3A5—Simvastatin—coronary artery disease	0.0101	0.0276	CbGbCtD
Thalidomide—CYP3A5—Lovastatin—coronary artery disease	0.00986	0.027	CbGbCtD
Thalidomide—CYP3A5—Pravastatin—coronary artery disease	0.00986	0.027	CbGbCtD
Thalidomide—CYP2C9—Pitavastatin—coronary artery disease	0.00986	0.027	CbGbCtD
Thalidomide—CYP2C9—Valsartan—coronary artery disease	0.00959	0.0262	CbGbCtD
Thalidomide—CYP2C19—Timolol—coronary artery disease	0.00956	0.0261	CbGbCtD
Thalidomide—CYP3A5—Atorvastatin—coronary artery disease	0.00898	0.0246	CbGbCtD
Thalidomide—CYP2C19—Rosuvastatin—coronary artery disease	0.00874	0.0239	CbGbCtD
Thalidomide—CYP2C19—Acetylsalicylic acid—coronary artery disease	0.00852	0.0233	CbGbCtD
Thalidomide—CYP3A5—Losartan—coronary artery disease	0.00821	0.0225	CbGbCtD
Thalidomide—CYP2C19—Simvastatin—coronary artery disease	0.00813	0.0222	CbGbCtD
Thalidomide—CYP2C19—Lovastatin—coronary artery disease	0.00795	0.0218	CbGbCtD
Thalidomide—CYP2C9—Rosuvastatin—coronary artery disease	0.00727	0.0199	CbGbCtD
Thalidomide—CYP2C19—Atorvastatin—coronary artery disease	0.00724	0.0198	CbGbCtD
Thalidomide—CYP2C9—Acetylsalicylic acid—coronary artery disease	0.00708	0.0194	CbGbCtD
Thalidomide—CYP2C9—Simvastatin—coronary artery disease	0.00676	0.0185	CbGbCtD
Thalidomide—CYP2C19—Losartan—coronary artery disease	0.00662	0.0181	CbGbCtD
Thalidomide—CYP2C9—Pravastatin—coronary artery disease	0.00661	0.0181	CbGbCtD
Thalidomide—CYP2C9—Lovastatin—coronary artery disease	0.00661	0.0181	CbGbCtD
Thalidomide—CYP1A2—Losartan—coronary artery disease	0.00611	0.0167	CbGbCtD
Thalidomide—CYP2C9—Atorvastatin—coronary artery disease	0.00602	0.0165	CbGbCtD
Thalidomide—CYP2C9—Losartan—coronary artery disease	0.00551	0.0151	CbGbCtD
Thalidomide—CYP2C9—cardial valve—coronary artery disease	0.00489	0.197	CbGeAlD
Thalidomide—NFKB1—myocardium—coronary artery disease	0.00148	0.0597	CbGeAlD
Thalidomide—TNF—blood—coronary artery disease	0.00135	0.0546	CbGeAlD
Thalidomide—Menadione—F7—coronary artery disease	0.00135	0.331	CrCbGaD
Thalidomide—CRBN—cardiac ventricle—coronary artery disease	0.00132	0.0532	CbGeAlD
Thalidomide—CRBN—myocardium—coronary artery disease	0.00124	0.0501	CbGeAlD
Thalidomide—Menadione—VKORC1—coronary artery disease	0.00114	0.281	CrCbGaD
Thalidomide—NFKB1—heart—coronary artery disease	0.00103	0.0417	CbGeAlD
Thalidomide—NFKB1—cardiovascular system—coronary artery disease	0.000974	0.0393	CbGeAlD
Thalidomide—NFKB1—cardiac atrium—coronary artery disease	0.000883	0.0357	CbGeAlD
Thalidomide—CRBN—heart—coronary artery disease	0.000866	0.0349	CbGeAlD
Thalidomide—NFKB1—blood—coronary artery disease	0.000771	0.0311	CbGeAlD
Thalidomide—CRBN—cardiac atrium—coronary artery disease	0.00074	0.0299	CbGeAlD
Thalidomide—FGFR2—cardiovascular system—coronary artery disease	0.000732	0.0295	CbGeAlD
Thalidomide—PTGS1—artery—coronary artery disease	0.00067	0.027	CbGeAlD
Thalidomide—CRBN—blood—coronary artery disease	0.000646	0.0261	CbGeAlD
Thalidomide—PTGS2—artery—coronary artery disease	0.00064	0.0258	CbGeAlD
Thalidomide—FGFR2—blood—coronary artery disease	0.000579	0.0234	CbGeAlD
Thalidomide—PTGS1—endothelium—coronary artery disease	0.000566	0.0228	CbGeAlD
Thalidomide—PTGS2—endothelium—coronary artery disease	0.000541	0.0218	CbGeAlD
Thalidomide—Pomalidomide—TNF—coronary artery disease	0.000454	0.112	CrCbGaD
Thalidomide—CYP1A1—cardiac ventricle—coronary artery disease	0.000427	0.0173	CbGeAlD
Thalidomide—Menadione—F2—coronary artery disease	0.000413	0.101	CrCbGaD
Thalidomide—PTGS1—myocardium—coronary artery disease	0.000353	0.0143	CbGeAlD
Thalidomide—CYP1A1—heart—coronary artery disease	0.000281	0.0113	CbGeAlD
Thalidomide—CYP2C9—heart—coronary artery disease	0.00027	0.0109	CbGeAlD
Thalidomide—Menadione—MTHFR—coronary artery disease	0.000264	0.065	CrCbGaD
Thalidomide—CYP2C19—blood—coronary artery disease	0.00026	0.0105	CbGeAlD
Thalidomide—CYP2C9—cardiovascular system—coronary artery disease	0.000255	0.0103	CbGeAlD
Thalidomide—PTGS1—heart—coronary artery disease	0.000247	0.00995	CbGeAlD
Thalidomide—CYP2E1—cardiovascular system—coronary artery disease	0.000242	0.00975	CbGeAlD
Thalidomide—CYP1A1—cardiac atrium—coronary artery disease	0.00024	0.00969	CbGeAlD
Thalidomide—PTGS2—heart—coronary artery disease	0.000236	0.00951	CbGeAlD
Thalidomide—PTGS1—cardiovascular system—coronary artery disease	0.000233	0.00939	CbGeAlD
Thalidomide—Lenalidomide—PTGS2—coronary artery disease	0.000232	0.057	CrCbGaD
Thalidomide—PTGS2—cardiovascular system—coronary artery disease	0.000222	0.00898	CbGeAlD
Thalidomide—Pomalidomide—PTGS2—coronary artery disease	0.000216	0.053	CrCbGaD
Thalidomide—CYP1A2—blood—coronary artery disease	0.000212	0.00857	CbGeAlD
Thalidomide—PTGS1—cardiac atrium—coronary artery disease	0.000211	0.00851	CbGeAlD
Thalidomide—CYP1A1—blood—coronary artery disease	0.000209	0.00846	CbGeAlD
Thalidomide—CYP3A5—blood—coronary artery disease	0.000205	0.00827	CbGeAlD
Thalidomide—CYP2C9—blood—coronary artery disease	0.000202	0.00814	CbGeAlD
Thalidomide—CYP2E1—blood—coronary artery disease	0.000191	0.00771	CbGeAlD
Thalidomide—PTGS1—blood—coronary artery disease	0.000184	0.00743	CbGeAlD
Thalidomide—PTGS2—blood—coronary artery disease	0.000176	0.0071	CbGeAlD
Thalidomide—Asthenia—Niacin—coronary artery disease	2.79e-05	0.000157	CcSEcCtD
Thalidomide—Fatigue—Losartan—coronary artery disease	2.79e-05	0.000156	CcSEcCtD
Thalidomide—Headache—Ezetimibe—coronary artery disease	2.78e-05	0.000156	CcSEcCtD
Thalidomide—Malaise—Lisinopril—coronary artery disease	2.78e-05	0.000156	CcSEcCtD
Thalidomide—Oedema—Ramipril—coronary artery disease	2.77e-05	0.000156	CcSEcCtD
Thalidomide—Vertigo—Lisinopril—coronary artery disease	2.77e-05	0.000155	CcSEcCtD
Thalidomide—Dry mouth—Timolol—coronary artery disease	2.77e-05	0.000155	CcSEcCtD
Thalidomide—Pain—Losartan—coronary artery disease	2.77e-05	0.000155	CcSEcCtD
Thalidomide—Constipation—Losartan—coronary artery disease	2.77e-05	0.000155	CcSEcCtD
Thalidomide—Syncope—Lisinopril—coronary artery disease	2.76e-05	0.000155	CcSEcCtD
Thalidomide—Vomiting—Eplerenone—coronary artery disease	2.76e-05	0.000155	CcSEcCtD
Thalidomide—Feeling abnormal—Furosemide—coronary artery disease	2.76e-05	0.000155	CcSEcCtD
Thalidomide—Leukopenia—Lisinopril—coronary artery disease	2.76e-05	0.000155	CcSEcCtD
Thalidomide—Nausea—Fenofibrate—coronary artery disease	2.75e-05	0.000155	CcSEcCtD
Thalidomide—Pruritus—Niacin—coronary artery disease	2.75e-05	0.000154	CcSEcCtD
Thalidomide—Asthenia—Pravastatin—coronary artery disease	2.75e-05	0.000154	CcSEcCtD
Thalidomide—Gastrointestinal pain—Furosemide—coronary artery disease	2.74e-05	0.000154	CcSEcCtD
Thalidomide—Rash—Eplerenone—coronary artery disease	2.74e-05	0.000154	CcSEcCtD
Thalidomide—Urticaria—Perindopril—coronary artery disease	2.74e-05	0.000154	CcSEcCtD
Thalidomide—Hypersensitivity—Trandolapril—coronary artery disease	2.74e-05	0.000154	CcSEcCtD
Thalidomide—Dermatitis—Eplerenone—coronary artery disease	2.74e-05	0.000154	CcSEcCtD
Thalidomide—Diarrhoea—Valsartan—coronary artery disease	2.74e-05	0.000154	CcSEcCtD
Thalidomide—Confusional state—Timolol—coronary artery disease	2.73e-05	0.000153	CcSEcCtD
Thalidomide—Shock—Ramipril—coronary artery disease	2.73e-05	0.000153	CcSEcCtD
Thalidomide—Hypersensitivity—Enalapril—coronary artery disease	2.73e-05	0.000153	CcSEcCtD
Thalidomide—Body temperature increased—Perindopril—coronary artery disease	2.73e-05	0.000153	CcSEcCtD
Thalidomide—Abdominal pain—Perindopril—coronary artery disease	2.73e-05	0.000153	CcSEcCtD
Thalidomide—Palpitations—Lisinopril—coronary artery disease	2.72e-05	0.000153	CcSEcCtD
Thalidomide—Diarrhoea—Olmesartan—coronary artery disease	2.72e-05	0.000153	CcSEcCtD
Thalidomide—Headache—Eplerenone—coronary artery disease	2.72e-05	0.000153	CcSEcCtD
Thalidomide—Nervous system disorder—Ramipril—coronary artery disease	2.72e-05	0.000153	CcSEcCtD
Thalidomide—Thrombocytopenia—Ramipril—coronary artery disease	2.71e-05	0.000152	CcSEcCtD
Thalidomide—Oedema—Timolol—coronary artery disease	2.71e-05	0.000152	CcSEcCtD
Thalidomide—Pruritus—Pravastatin—coronary artery disease	2.71e-05	0.000152	CcSEcCtD
Thalidomide—Loss of consciousness—Lisinopril—coronary artery disease	2.71e-05	0.000152	CcSEcCtD
Thalidomide—Nausea—Clopidogrel—coronary artery disease	2.71e-05	0.000152	CcSEcCtD
Thalidomide—Tachycardia—Ramipril—coronary artery disease	2.71e-05	0.000152	CcSEcCtD
Thalidomide—Skin disorder—Ramipril—coronary artery disease	2.69e-05	0.000151	CcSEcCtD
Thalidomide—Infection—Timolol—coronary artery disease	2.69e-05	0.000151	CcSEcCtD
Thalidomide—Vomiting—Simvastatin—coronary artery disease	2.69e-05	0.000151	CcSEcCtD
Thalidomide—Hypersensitivity—Telmisartan—coronary artery disease	2.69e-05	0.000151	CcSEcCtD
Thalidomide—Cough—Lisinopril—coronary artery disease	2.69e-05	0.000151	CcSEcCtD
Thalidomide—Nausea—Lovastatin—coronary artery disease	2.69e-05	0.000151	CcSEcCtD
Thalidomide—Hyperhidrosis—Ramipril—coronary artery disease	2.68e-05	0.00015	CcSEcCtD
Thalidomide—Rash—Simvastatin—coronary artery disease	2.67e-05	0.00015	CcSEcCtD
Thalidomide—Dermatitis—Simvastatin—coronary artery disease	2.67e-05	0.00015	CcSEcCtD
Thalidomide—Asthenia—Trandolapril—coronary artery disease	2.67e-05	0.00015	CcSEcCtD
Thalidomide—Shock—Timolol—coronary artery disease	2.67e-05	0.00015	CcSEcCtD
Thalidomide—Feeling abnormal—Losartan—coronary artery disease	2.66e-05	0.00015	CcSEcCtD
Thalidomide—Urticaria—Furosemide—coronary artery disease	2.66e-05	0.000149	CcSEcCtD
Thalidomide—Diarrhoea—Niacin—coronary artery disease	2.66e-05	0.000149	CcSEcCtD
Thalidomide—Nervous system disorder—Timolol—coronary artery disease	2.66e-05	0.000149	CcSEcCtD
Thalidomide—Asthenia—Enalapril—coronary artery disease	2.66e-05	0.000149	CcSEcCtD
Thalidomide—Headache—Simvastatin—coronary artery disease	2.65e-05	0.000149	CcSEcCtD
Thalidomide—Body temperature increased—Furosemide—coronary artery disease	2.65e-05	0.000149	CcSEcCtD
Thalidomide—Abdominal pain—Furosemide—coronary artery disease	2.65e-05	0.000149	CcSEcCtD
Thalidomide—Gastrointestinal pain—Losartan—coronary artery disease	2.64e-05	0.000148	CcSEcCtD
Thalidomide—Dizziness—Valsartan—coronary artery disease	2.64e-05	0.000148	CcSEcCtD
Thalidomide—Anorexia—Ramipril—coronary artery disease	2.64e-05	0.000148	CcSEcCtD
Thalidomide—Nausea—Ezetimibe—coronary artery disease	2.64e-05	0.000148	CcSEcCtD
Thalidomide—Skin disorder—Timolol—coronary artery disease	2.63e-05	0.000148	CcSEcCtD
Thalidomide—Dizziness—Olmesartan—coronary artery disease	2.63e-05	0.000148	CcSEcCtD
Thalidomide—Pruritus—Trandolapril—coronary artery disease	2.63e-05	0.000148	CcSEcCtD
Thalidomide—Chest pain—Lisinopril—coronary artery disease	2.62e-05	0.000147	CcSEcCtD
Thalidomide—Myalgia—Lisinopril—coronary artery disease	2.62e-05	0.000147	CcSEcCtD
Thalidomide—Arthralgia—Lisinopril—coronary artery disease	2.62e-05	0.000147	CcSEcCtD
Thalidomide—Hyperhidrosis—Timolol—coronary artery disease	2.62e-05	0.000147	CcSEcCtD
Thalidomide—Asthenia—Telmisartan—coronary artery disease	2.62e-05	0.000147	CcSEcCtD
Thalidomide—Pruritus—Enalapril—coronary artery disease	2.62e-05	0.000147	CcSEcCtD
Thalidomide—Diarrhoea—Pravastatin—coronary artery disease	2.62e-05	0.000147	CcSEcCtD
Thalidomide—Anxiety—Lisinopril—coronary artery disease	2.61e-05	0.000147	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—coronary artery disease	2.61e-05	0.000146	CcSEcCtD
Thalidomide—Discomfort—Lisinopril—coronary artery disease	2.59e-05	0.000145	CcSEcCtD
Thalidomide—Hypotension—Ramipril—coronary artery disease	2.59e-05	0.000145	CcSEcCtD
Thalidomide—Anorexia—Timolol—coronary artery disease	2.58e-05	0.000145	CcSEcCtD
Thalidomide—Pruritus—Telmisartan—coronary artery disease	2.58e-05	0.000145	CcSEcCtD
Thalidomide—Nausea—Eplerenone—coronary artery disease	2.58e-05	0.000145	CcSEcCtD
Thalidomide—Dizziness—Niacin—coronary artery disease	2.57e-05	0.000144	CcSEcCtD
Thalidomide—Urticaria—Losartan—coronary artery disease	2.57e-05	0.000144	CcSEcCtD
Thalidomide—Dry mouth—Lisinopril—coronary artery disease	2.57e-05	0.000144	CcSEcCtD
Thalidomide—Body temperature increased—Losartan—coronary artery disease	2.56e-05	0.000143	CcSEcCtD
Thalidomide—Abdominal pain—Losartan—coronary artery disease	2.56e-05	0.000143	CcSEcCtD
Thalidomide—Asthenia—Captopril—coronary artery disease	2.55e-05	0.000143	CcSEcCtD
Thalidomide—Diarrhoea—Trandolapril—coronary artery disease	2.54e-05	0.000143	CcSEcCtD
Thalidomide—Vomiting—Valsartan—coronary artery disease	2.54e-05	0.000143	CcSEcCtD
Thalidomide—Confusional state—Lisinopril—coronary artery disease	2.54e-05	0.000142	CcSEcCtD
Thalidomide—Diarrhoea—Enalapril—coronary artery disease	2.53e-05	0.000142	CcSEcCtD
Thalidomide—Hypotension—Timolol—coronary artery disease	2.53e-05	0.000142	CcSEcCtD
Thalidomide—Dizziness—Pravastatin—coronary artery disease	2.53e-05	0.000142	CcSEcCtD
Thalidomide—Vomiting—Olmesartan—coronary artery disease	2.53e-05	0.000142	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Ramipril—coronary artery disease	2.53e-05	0.000142	CcSEcCtD
Thalidomide—Rash—Valsartan—coronary artery disease	2.52e-05	0.000141	CcSEcCtD
Thalidomide—Dermatitis—Valsartan—coronary artery disease	2.52e-05	0.000141	CcSEcCtD
Thalidomide—Nausea—Simvastatin—coronary artery disease	2.51e-05	0.000141	CcSEcCtD
Thalidomide—Oedema—Lisinopril—coronary artery disease	2.51e-05	0.000141	CcSEcCtD
Thalidomide—Pruritus—Captopril—coronary artery disease	2.51e-05	0.000141	CcSEcCtD
Thalidomide—Rash—Olmesartan—coronary artery disease	2.51e-05	0.000141	CcSEcCtD
Thalidomide—Insomnia—Ramipril—coronary artery disease	2.51e-05	0.000141	CcSEcCtD
Thalidomide—Dermatitis—Olmesartan—coronary artery disease	2.51e-05	0.000141	CcSEcCtD
Thalidomide—Headache—Valsartan—coronary artery disease	2.5e-05	0.000141	CcSEcCtD
Thalidomide—Diarrhoea—Telmisartan—coronary artery disease	2.5e-05	0.00014	CcSEcCtD
Thalidomide—Infection—Lisinopril—coronary artery disease	2.5e-05	0.00014	CcSEcCtD
Thalidomide—Headache—Olmesartan—coronary artery disease	2.49e-05	0.00014	CcSEcCtD
Thalidomide—Paraesthesia—Ramipril—coronary artery disease	2.49e-05	0.00014	CcSEcCtD
Thalidomide—Shock—Lisinopril—coronary artery disease	2.47e-05	0.000139	CcSEcCtD
Thalidomide—Asthenia—Perindopril—coronary artery disease	2.47e-05	0.000139	CcSEcCtD
Thalidomide—Dyspnoea—Ramipril—coronary artery disease	2.47e-05	0.000139	CcSEcCtD
Thalidomide—Vomiting—Niacin—coronary artery disease	2.47e-05	0.000139	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Timolol—coronary artery disease	2.47e-05	0.000139	CcSEcCtD
Thalidomide—Hypersensitivity—Furosemide—coronary artery disease	2.47e-05	0.000139	CcSEcCtD
Thalidomide—Somnolence—Ramipril—coronary artery disease	2.46e-05	0.000138	CcSEcCtD
Thalidomide—Thrombocytopenia—Lisinopril—coronary artery disease	2.46e-05	0.000138	CcSEcCtD
Thalidomide—Dizziness—Trandolapril—coronary artery disease	2.46e-05	0.000138	CcSEcCtD
Thalidomide—Tachycardia—Lisinopril—coronary artery disease	2.45e-05	0.000138	CcSEcCtD
Thalidomide—Insomnia—Timolol—coronary artery disease	2.45e-05	0.000138	CcSEcCtD
Thalidomide—Rash—Niacin—coronary artery disease	2.45e-05	0.000138	CcSEcCtD
Thalidomide—Dermatitis—Niacin—coronary artery disease	2.45e-05	0.000137	CcSEcCtD
Thalidomide—Dizziness—Enalapril—coronary artery disease	2.45e-05	0.000137	CcSEcCtD
Thalidomide—Skin disorder—Lisinopril—coronary artery disease	2.44e-05	0.000137	CcSEcCtD
Thalidomide—Dyspepsia—Ramipril—coronary artery disease	2.44e-05	0.000137	CcSEcCtD
Thalidomide—Pruritus—Perindopril—coronary artery disease	2.44e-05	0.000137	CcSEcCtD
Thalidomide—Headache—Niacin—coronary artery disease	2.44e-05	0.000137	CcSEcCtD
Thalidomide—Paraesthesia—Timolol—coronary artery disease	2.43e-05	0.000137	CcSEcCtD
Thalidomide—Vomiting—Pravastatin—coronary artery disease	2.43e-05	0.000137	CcSEcCtD
Thalidomide—Hyperhidrosis—Lisinopril—coronary artery disease	2.43e-05	0.000136	CcSEcCtD
Thalidomide—Diarrhoea—Captopril—coronary artery disease	2.43e-05	0.000136	CcSEcCtD
Thalidomide—Dyspnoea—Timolol—coronary artery disease	2.42e-05	0.000136	CcSEcCtD
Thalidomide—Dizziness—Telmisartan—coronary artery disease	2.41e-05	0.000136	CcSEcCtD
Thalidomide—Rash—Pravastatin—coronary artery disease	2.41e-05	0.000135	CcSEcCtD
Thalidomide—Dermatitis—Pravastatin—coronary artery disease	2.41e-05	0.000135	CcSEcCtD
Thalidomide—Decreased appetite—Ramipril—coronary artery disease	2.41e-05	0.000135	CcSEcCtD
Thalidomide—Somnolence—Timolol—coronary artery disease	2.41e-05	0.000135	CcSEcCtD
Thalidomide—Asthenia—Furosemide—coronary artery disease	2.4e-05	0.000135	CcSEcCtD
Thalidomide—Headache—Pravastatin—coronary artery disease	2.4e-05	0.000135	CcSEcCtD
Thalidomide—Anorexia—Lisinopril—coronary artery disease	2.4e-05	0.000135	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Ramipril—coronary artery disease	2.39e-05	0.000134	CcSEcCtD
Thalidomide—Fatigue—Ramipril—coronary artery disease	2.39e-05	0.000134	CcSEcCtD
Thalidomide—Dyspepsia—Timolol—coronary artery disease	2.39e-05	0.000134	CcSEcCtD
Thalidomide—Hypersensitivity—Losartan—coronary artery disease	2.38e-05	0.000134	CcSEcCtD
Thalidomide—Nausea—Valsartan—coronary artery disease	2.37e-05	0.000133	CcSEcCtD
Thalidomide—Pruritus—Furosemide—coronary artery disease	2.37e-05	0.000133	CcSEcCtD
Thalidomide—Constipation—Ramipril—coronary artery disease	2.37e-05	0.000133	CcSEcCtD
Thalidomide—Nausea—Olmesartan—coronary artery disease	2.36e-05	0.000133	CcSEcCtD
Thalidomide—Vomiting—Trandolapril—coronary artery disease	2.36e-05	0.000133	CcSEcCtD
Thalidomide—Diarrhoea—Perindopril—coronary artery disease	2.36e-05	0.000132	CcSEcCtD
Thalidomide—Decreased appetite—Timolol—coronary artery disease	2.36e-05	0.000132	CcSEcCtD
Thalidomide—Vomiting—Enalapril—coronary artery disease	2.35e-05	0.000132	CcSEcCtD
Thalidomide—Hypotension—Lisinopril—coronary artery disease	2.35e-05	0.000132	CcSEcCtD
Thalidomide—Dizziness—Captopril—coronary artery disease	2.35e-05	0.000132	CcSEcCtD
Thalidomide—Rash—Trandolapril—coronary artery disease	2.34e-05	0.000132	CcSEcCtD
Thalidomide—Dermatitis—Trandolapril—coronary artery disease	2.34e-05	0.000131	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Timolol—coronary artery disease	2.34e-05	0.000131	CcSEcCtD
Thalidomide—Fatigue—Timolol—coronary artery disease	2.34e-05	0.000131	CcSEcCtD
Thalidomide—Rash—Enalapril—coronary artery disease	2.33e-05	0.000131	CcSEcCtD
Thalidomide—Dermatitis—Enalapril—coronary artery disease	2.33e-05	0.000131	CcSEcCtD
Thalidomide—Headache—Trandolapril—coronary artery disease	2.33e-05	0.000131	CcSEcCtD
Thalidomide—Vomiting—Telmisartan—coronary artery disease	2.32e-05	0.00013	CcSEcCtD
Thalidomide—Asthenia—Losartan—coronary artery disease	2.32e-05	0.00013	CcSEcCtD
Thalidomide—Headache—Enalapril—coronary artery disease	2.32e-05	0.00013	CcSEcCtD
Thalidomide—Pain—Timolol—coronary artery disease	2.32e-05	0.00013	CcSEcCtD
Thalidomide—Nausea—Niacin—coronary artery disease	2.31e-05	0.00013	CcSEcCtD
Thalidomide—Rash—Telmisartan—coronary artery disease	2.3e-05	0.000129	CcSEcCtD
Thalidomide—Dermatitis—Telmisartan—coronary artery disease	2.3e-05	0.000129	CcSEcCtD
Thalidomide—Diarrhoea—Furosemide—coronary artery disease	2.29e-05	0.000129	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Lisinopril—coronary artery disease	2.29e-05	0.000129	CcSEcCtD
Thalidomide—Pruritus—Losartan—coronary artery disease	2.29e-05	0.000128	CcSEcCtD
Thalidomide—Headache—Telmisartan—coronary artery disease	2.29e-05	0.000128	CcSEcCtD
Thalidomide—Feeling abnormal—Ramipril—coronary artery disease	2.28e-05	0.000128	CcSEcCtD
Thalidomide—Dizziness—Perindopril—coronary artery disease	2.28e-05	0.000128	CcSEcCtD
Thalidomide—Insomnia—Lisinopril—coronary artery disease	2.27e-05	0.000128	CcSEcCtD
Thalidomide—Nausea—Pravastatin—coronary artery disease	2.27e-05	0.000128	CcSEcCtD
Thalidomide—Gastrointestinal pain—Ramipril—coronary artery disease	2.27e-05	0.000127	CcSEcCtD
Thalidomide—Paraesthesia—Lisinopril—coronary artery disease	2.26e-05	0.000127	CcSEcCtD
Thalidomide—Vomiting—Captopril—coronary artery disease	2.26e-05	0.000127	CcSEcCtD
Thalidomide—Dyspnoea—Lisinopril—coronary artery disease	2.24e-05	0.000126	CcSEcCtD
Thalidomide—Rash—Captopril—coronary artery disease	2.24e-05	0.000126	CcSEcCtD
Thalidomide—Dermatitis—Captopril—coronary artery disease	2.24e-05	0.000126	CcSEcCtD
Thalidomide—Somnolence—Lisinopril—coronary artery disease	2.24e-05	0.000125	CcSEcCtD
Thalidomide—Feeling abnormal—Timolol—coronary artery disease	2.23e-05	0.000125	CcSEcCtD
Thalidomide—Headache—Captopril—coronary artery disease	2.22e-05	0.000125	CcSEcCtD
Thalidomide—Gastrointestinal pain—Timolol—coronary artery disease	2.22e-05	0.000124	CcSEcCtD
Thalidomide—Dizziness—Furosemide—coronary artery disease	2.22e-05	0.000124	CcSEcCtD
Thalidomide—Dyspepsia—Lisinopril—coronary artery disease	2.21e-05	0.000124	CcSEcCtD
Thalidomide—Diarrhoea—Losartan—coronary artery disease	2.21e-05	0.000124	CcSEcCtD
Thalidomide—Nausea—Trandolapril—coronary artery disease	2.21e-05	0.000124	CcSEcCtD
Thalidomide—Urticaria—Ramipril—coronary artery disease	2.2e-05	0.000124	CcSEcCtD
Thalidomide—Nausea—Enalapril—coronary artery disease	2.2e-05	0.000123	CcSEcCtD
Thalidomide—Vomiting—Perindopril—coronary artery disease	2.19e-05	0.000123	CcSEcCtD
Thalidomide—Abdominal pain—Ramipril—coronary artery disease	2.19e-05	0.000123	CcSEcCtD
Thalidomide—Body temperature increased—Ramipril—coronary artery disease	2.19e-05	0.000123	CcSEcCtD
Thalidomide—Decreased appetite—Lisinopril—coronary artery disease	2.19e-05	0.000123	CcSEcCtD
Thalidomide—Rash—Perindopril—coronary artery disease	2.17e-05	0.000122	CcSEcCtD
Thalidomide—Dermatitis—Perindopril—coronary artery disease	2.17e-05	0.000122	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Lisinopril—coronary artery disease	2.17e-05	0.000122	CcSEcCtD
Thalidomide—Nausea—Telmisartan—coronary artery disease	2.17e-05	0.000122	CcSEcCtD
Thalidomide—Fatigue—Lisinopril—coronary artery disease	2.17e-05	0.000122	CcSEcCtD
Thalidomide—Headache—Perindopril—coronary artery disease	2.16e-05	0.000121	CcSEcCtD
Thalidomide—Urticaria—Timolol—coronary artery disease	2.15e-05	0.000121	CcSEcCtD
Thalidomide—Pain—Lisinopril—coronary artery disease	2.15e-05	0.000121	CcSEcCtD
Thalidomide—Constipation—Lisinopril—coronary artery disease	2.15e-05	0.000121	CcSEcCtD
Thalidomide—Body temperature increased—Timolol—coronary artery disease	2.14e-05	0.00012	CcSEcCtD
Thalidomide—Abdominal pain—Timolol—coronary artery disease	2.14e-05	0.00012	CcSEcCtD
Thalidomide—Dizziness—Losartan—coronary artery disease	2.14e-05	0.00012	CcSEcCtD
Thalidomide—Vomiting—Furosemide—coronary artery disease	2.13e-05	0.00012	CcSEcCtD
Thalidomide—Rash—Furosemide—coronary artery disease	2.11e-05	0.000119	CcSEcCtD
Thalidomide—Dermatitis—Furosemide—coronary artery disease	2.11e-05	0.000118	CcSEcCtD
Thalidomide—Nausea—Captopril—coronary artery disease	2.11e-05	0.000118	CcSEcCtD
Thalidomide—Headache—Furosemide—coronary artery disease	2.1e-05	0.000118	CcSEcCtD
Thalidomide—Feeling abnormal—Lisinopril—coronary artery disease	2.07e-05	0.000116	CcSEcCtD
Thalidomide—Gastrointestinal pain—Lisinopril—coronary artery disease	2.06e-05	0.000115	CcSEcCtD
Thalidomide—Vomiting—Losartan—coronary artery disease	2.06e-05	0.000115	CcSEcCtD
Thalidomide—Nausea—Perindopril—coronary artery disease	2.05e-05	0.000115	CcSEcCtD
Thalidomide—Hypersensitivity—Ramipril—coronary artery disease	2.04e-05	0.000115	CcSEcCtD
Thalidomide—Rash—Losartan—coronary artery disease	2.04e-05	0.000114	CcSEcCtD
Thalidomide—Dermatitis—Losartan—coronary artery disease	2.04e-05	0.000114	CcSEcCtD
Thalidomide—Headache—Losartan—coronary artery disease	2.03e-05	0.000114	CcSEcCtD
Thalidomide—Urticaria—Lisinopril—coronary artery disease	2e-05	0.000112	CcSEcCtD
Thalidomide—Hypersensitivity—Timolol—coronary artery disease	2e-05	0.000112	CcSEcCtD
Thalidomide—Nausea—Furosemide—coronary artery disease	1.99e-05	0.000112	CcSEcCtD
Thalidomide—Asthenia—Ramipril—coronary artery disease	1.99e-05	0.000112	CcSEcCtD
Thalidomide—Abdominal pain—Lisinopril—coronary artery disease	1.99e-05	0.000112	CcSEcCtD
Thalidomide—Body temperature increased—Lisinopril—coronary artery disease	1.99e-05	0.000112	CcSEcCtD
Thalidomide—Pruritus—Ramipril—coronary artery disease	1.96e-05	0.00011	CcSEcCtD
Thalidomide—Asthenia—Timolol—coronary artery disease	1.94e-05	0.000109	CcSEcCtD
Thalidomide—Nausea—Losartan—coronary artery disease	1.92e-05	0.000108	CcSEcCtD
Thalidomide—Pruritus—Timolol—coronary artery disease	1.92e-05	0.000108	CcSEcCtD
Thalidomide—Diarrhoea—Ramipril—coronary artery disease	1.9e-05	0.000106	CcSEcCtD
Thalidomide—Diarrhoea—Timolol—coronary artery disease	1.85e-05	0.000104	CcSEcCtD
Thalidomide—Hypersensitivity—Lisinopril—coronary artery disease	1.85e-05	0.000104	CcSEcCtD
Thalidomide—Dizziness—Ramipril—coronary artery disease	1.83e-05	0.000103	CcSEcCtD
Thalidomide—Asthenia—Lisinopril—coronary artery disease	1.8e-05	0.000101	CcSEcCtD
Thalidomide—Dizziness—Timolol—coronary artery disease	1.79e-05	0.000101	CcSEcCtD
Thalidomide—Pruritus—Lisinopril—coronary artery disease	1.78e-05	9.99e-05	CcSEcCtD
Thalidomide—Vomiting—Ramipril—coronary artery disease	1.76e-05	9.89e-05	CcSEcCtD
Thalidomide—Rash—Ramipril—coronary artery disease	1.75e-05	9.81e-05	CcSEcCtD
Thalidomide—Dermatitis—Ramipril—coronary artery disease	1.75e-05	9.8e-05	CcSEcCtD
Thalidomide—Headache—Ramipril—coronary artery disease	1.74e-05	9.75e-05	CcSEcCtD
Thalidomide—Vomiting—Timolol—coronary artery disease	1.72e-05	9.67e-05	CcSEcCtD
Thalidomide—Diarrhoea—Lisinopril—coronary artery disease	1.72e-05	9.66e-05	CcSEcCtD
Thalidomide—Rash—Timolol—coronary artery disease	1.71e-05	9.59e-05	CcSEcCtD
Thalidomide—Dermatitis—Timolol—coronary artery disease	1.71e-05	9.58e-05	CcSEcCtD
Thalidomide—Headache—Timolol—coronary artery disease	1.7e-05	9.53e-05	CcSEcCtD
Thalidomide—Dizziness—Lisinopril—coronary artery disease	1.66e-05	9.33e-05	CcSEcCtD
Thalidomide—Nausea—Ramipril—coronary artery disease	1.65e-05	9.24e-05	CcSEcCtD
Thalidomide—Nausea—Timolol—coronary artery disease	1.61e-05	9.04e-05	CcSEcCtD
Thalidomide—Vomiting—Lisinopril—coronary artery disease	1.6e-05	8.97e-05	CcSEcCtD
Thalidomide—Rash—Lisinopril—coronary artery disease	1.59e-05	8.9e-05	CcSEcCtD
Thalidomide—Dermatitis—Lisinopril—coronary artery disease	1.58e-05	8.89e-05	CcSEcCtD
Thalidomide—Headache—Lisinopril—coronary artery disease	1.58e-05	8.84e-05	CcSEcCtD
Thalidomide—Nausea—Lisinopril—coronary artery disease	1.49e-05	8.38e-05	CcSEcCtD
Thalidomide—CYP3A5—Metabolism—GSTP1—coronary artery disease	1.78e-06	1.34e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GOT2—coronary artery disease	1.78e-06	1.34e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—HMGCR—coronary artery disease	1.78e-06	1.34e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—SDC1—coronary artery disease	1.77e-06	1.33e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PPARGC1A—coronary artery disease	1.77e-06	1.33e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PPARGC1A—coronary artery disease	1.76e-06	1.33e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—HMOX1—coronary artery disease	1.76e-06	1.33e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—JAK2—coronary artery disease	1.76e-06	1.32e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—HMOX1—coronary artery disease	1.76e-06	1.32e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HIF1A—coronary artery disease	1.75e-06	1.32e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GSTM1—coronary artery disease	1.74e-06	1.31e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CAT—coronary artery disease	1.74e-06	1.31e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—VCAN—coronary artery disease	1.74e-06	1.31e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CAT—coronary artery disease	1.73e-06	1.31e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ALDOA—coronary artery disease	1.72e-06	1.3e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—APOE—coronary artery disease	1.71e-06	1.29e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—LPL—coronary artery disease	1.71e-06	1.29e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—coronary artery disease	1.71e-06	1.29e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—TGFB1—coronary artery disease	1.71e-06	1.29e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—APOA1—coronary artery disease	1.69e-06	1.28e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CXCL8—coronary artery disease	1.69e-06	1.27e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—APOB—coronary artery disease	1.69e-06	1.27e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GSTP1—coronary artery disease	1.68e-06	1.27e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—APOB—coronary artery disease	1.68e-06	1.27e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—MAPK1—coronary artery disease	1.67e-06	1.26e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—DCN—coronary artery disease	1.67e-06	1.26e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PSMB5—coronary artery disease	1.67e-06	1.26e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PSMA6—coronary artery disease	1.67e-06	1.26e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—coronary artery disease	1.67e-06	1.26e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GPX1—coronary artery disease	1.67e-06	1.26e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PPARGC1A—coronary artery disease	1.67e-06	1.26e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—HMOX1—coronary artery disease	1.66e-06	1.25e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—PIK3CA—coronary artery disease	1.66e-06	1.25e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GSTM1—coronary artery disease	1.64e-06	1.24e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CAT—coronary artery disease	1.64e-06	1.23e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GSTM1—coronary artery disease	1.64e-06	1.23e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CTGF—coronary artery disease	1.63e-06	1.23e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PLCB1—coronary artery disease	1.63e-06	1.23e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ALDH2—coronary artery disease	1.63e-06	1.23e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CD36—coronary artery disease	1.62e-06	1.22e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—HMGCR—coronary artery disease	1.62e-06	1.22e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GOT2—coronary artery disease	1.62e-06	1.22e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CASP3—coronary artery disease	1.62e-06	1.22e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—LPL—coronary artery disease	1.61e-06	1.21e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IL6ST—coronary artery disease	1.61e-06	1.21e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—LPL—coronary artery disease	1.61e-06	1.21e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PPP2CA—coronary artery disease	1.6e-06	1.21e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CXCL8—coronary artery disease	1.6e-06	1.21e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—coronary artery disease	1.6e-06	1.21e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NOS2—coronary artery disease	1.59e-06	1.2e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—APOB—coronary artery disease	1.59e-06	1.2e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—coronary artery disease	1.59e-06	1.2e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—HBA1—coronary artery disease	1.59e-06	1.2e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—LIPC—coronary artery disease	1.59e-06	1.2e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PIK3C2A—coronary artery disease	1.59e-06	1.2e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP2C19—coronary artery disease	1.59e-06	1.2e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ABCA1—coronary artery disease	1.58e-06	1.19e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—APOC3—coronary artery disease	1.58e-06	1.19e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CCND1—coronary artery disease	1.57e-06	1.19e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—PIK3CA—coronary artery disease	1.57e-06	1.19e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PPARG—coronary artery disease	1.57e-06	1.19e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GPX1—coronary artery disease	1.57e-06	1.18e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GPX1—coronary artery disease	1.57e-06	1.18e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—LDLR—coronary artery disease	1.57e-06	1.18e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—POMC—coronary artery disease	1.56e-06	1.18e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—POMC—coronary artery disease	1.55e-06	1.17e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GSTT1—coronary artery disease	1.55e-06	1.17e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SLC9A1—coronary artery disease	1.55e-06	1.17e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GSTM1—coronary artery disease	1.55e-06	1.17e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—KIT—coronary artery disease	1.54e-06	1.16e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—MTHFR—coronary artery disease	1.54e-06	1.16e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CASP3—coronary artery disease	1.53e-06	1.16e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GGT1—coronary artery disease	1.53e-06	1.16e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GOT1—coronary artery disease	1.53e-06	1.16e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GCLC—coronary artery disease	1.53e-06	1.15e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CETP—coronary artery disease	1.53e-06	1.15e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CD36—coronary artery disease	1.53e-06	1.15e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MMP9—coronary artery disease	1.53e-06	1.15e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CD36—coronary artery disease	1.53e-06	1.15e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—LPL—coronary artery disease	1.52e-06	1.14e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SDC1—coronary artery disease	1.51e-06	1.14e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PPP2CA—coronary artery disease	1.51e-06	1.14e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PPP2CA—coronary artery disease	1.51e-06	1.14e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCND1—coronary artery disease	1.49e-06	1.13e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PLCB1—coronary artery disease	1.49e-06	1.12e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—GSK3B—coronary artery disease	1.48e-06	1.12e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GPX1—coronary artery disease	1.48e-06	1.12e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CREB1—coronary artery disease	1.47e-06	1.11e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL6—coronary artery disease	1.47e-06	1.11e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—AGT—coronary artery disease	1.46e-06	1.1e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—coronary artery disease	1.46e-06	1.1e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PIK3CA—coronary artery disease	1.45e-06	1.1e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MMP9—coronary artery disease	1.45e-06	1.09e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—MTHFR—coronary artery disease	1.45e-06	1.09e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—MTHFR—coronary artery disease	1.45e-06	1.09e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ABCA1—coronary artery disease	1.44e-06	1.09e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CD36—coronary artery disease	1.44e-06	1.09e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IL6R—coronary artery disease	1.43e-06	1.08e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—APOE—coronary artery disease	1.43e-06	1.08e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PSMA6—coronary artery disease	1.43e-06	1.08e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PSMB5—coronary artery disease	1.43e-06	1.08e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—coronary artery disease	1.43e-06	1.08e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PPP2CA—coronary artery disease	1.42e-06	1.07e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—APOA1—coronary artery disease	1.42e-06	1.07e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ALB—coronary artery disease	1.41e-06	1.07e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GGT1—coronary artery disease	1.4e-06	1.05e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GOT1—coronary artery disease	1.4e-06	1.05e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CTGF—coronary artery disease	1.4e-06	1.05e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL6—coronary artery disease	1.39e-06	1.05e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—HMGCR—coronary artery disease	1.38e-06	1.04e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GOT2—coronary artery disease	1.38e-06	1.04e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—AGT—coronary artery disease	1.38e-06	1.04e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GSTP1—coronary artery disease	1.38e-06	1.04e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—AGT—coronary artery disease	1.37e-06	1.04e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—VEGFA—coronary artery disease	1.37e-06	1.03e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—MTHFR—coronary artery disease	1.37e-06	1.03e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PPARGC1A—coronary artery disease	1.36e-06	1.03e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—HMOX1—coronary artery disease	1.36e-06	1.02e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—coronary artery disease	1.36e-06	1.02e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—AKT1—coronary artery disease	1.35e-06	1.02e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—NOS3—coronary artery disease	1.35e-06	1.02e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—APOE—coronary artery disease	1.35e-06	1.02e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—APOE—coronary artery disease	1.35e-06	1.02e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—SERPINE1—coronary artery disease	1.34e-06	1.01e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CAT—coronary artery disease	1.34e-06	1.01e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—APOA1—coronary artery disease	1.33e-06	1.01e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—APOA1—coronary artery disease	1.33e-06	1e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—VEGFA—coronary artery disease	1.3e-06	9.82e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—APOB—coronary artery disease	1.3e-06	9.8e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—FGF2—coronary artery disease	1.3e-06	9.8e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—AGT—coronary artery disease	1.3e-06	9.79e-06	CbGpPWpGaD
Thalidomide—FGFR2—Disease—IL6—coronary artery disease	1.29e-06	9.7e-06	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—AKT1—coronary artery disease	1.29e-06	9.69e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NOS3—coronary artery disease	1.28e-06	9.67e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PLCB1—coronary artery disease	1.27e-06	9.59e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—APOE—coronary artery disease	1.27e-06	9.59e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GSTM1—coronary artery disease	1.27e-06	9.54e-06	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TGFB1—coronary artery disease	1.26e-06	9.5e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—APOA1—coronary artery disease	1.26e-06	9.48e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GSTP1—coronary artery disease	1.26e-06	9.46e-06	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PPARG—coronary artery disease	1.25e-06	9.41e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—coronary artery disease	1.25e-06	9.41e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—JAK2—coronary artery disease	1.25e-06	9.39e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PPARGC1A—coronary artery disease	1.24e-06	9.38e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—LPL—coronary artery disease	1.24e-06	9.36e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—HMOX1—coronary artery disease	1.24e-06	9.33e-06	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PTGS2—coronary artery disease	1.24e-06	9.33e-06	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MAPK1—coronary artery disease	1.24e-06	9.31e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ABCA1—coronary artery disease	1.23e-06	9.3e-06	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—POMC—coronary artery disease	1.23e-06	9.28e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CAT—coronary artery disease	1.22e-06	9.21e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GPX1—coronary artery disease	1.21e-06	9.13e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—coronary artery disease	1.2e-06	9.08e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TGFB1—coronary artery disease	1.2e-06	9.01e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GGT1—coronary artery disease	1.19e-06	9e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GOT1—coronary artery disease	1.19e-06	9e-06	CbGpPWpGaD
Thalidomide—FGFR2—Disease—AKT1—coronary artery disease	1.19e-06	8.95e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—APOB—coronary artery disease	1.19e-06	8.94e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CD36—coronary artery disease	1.18e-06	8.89e-06	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PPARG—coronary artery disease	1.18e-06	8.86e-06	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PPARG—coronary artery disease	1.17e-06	8.84e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MAPK1—coronary artery disease	1.17e-06	8.84e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PPP2CA—coronary artery disease	1.17e-06	8.78e-06	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—POMC—coronary artery disease	1.16e-06	8.74e-06	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—POMC—coronary artery disease	1.16e-06	8.72e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GSTM1—coronary artery disease	1.15e-06	8.7e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—LPL—coronary artery disease	1.13e-06	8.54e-06	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ALB—coronary artery disease	1.12e-06	8.46e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—MTHFR—coronary artery disease	1.12e-06	8.43e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PPARG—coronary artery disease	1.11e-06	8.35e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GPX1—coronary artery disease	1.1e-06	8.33e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—POMC—coronary artery disease	1.09e-06	8.24e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CD36—coronary artery disease	1.08e-06	8.11e-06	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—NOS3—coronary artery disease	1.07e-06	8.09e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GSTP1—coronary artery disease	1.07e-06	8.09e-06	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PIK3CA—coronary artery disease	1.07e-06	8.08e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PPARGC1A—coronary artery disease	1.06e-06	8.01e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PPP2CA—coronary artery disease	1.06e-06	8.01e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—AGT—coronary artery disease	1.06e-06	8.01e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—HMOX1—coronary artery disease	1.06e-06	7.98e-06	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ALB—coronary artery disease	1.06e-06	7.97e-06	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ALB—coronary artery disease	1.05e-06	7.95e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CAT—coronary artery disease	1.04e-06	7.87e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—APOE—coronary artery disease	1.04e-06	7.85e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—APOA1—coronary artery disease	1.03e-06	7.76e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—MTHFR—coronary artery disease	1.02e-06	7.69e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PIK3CA—coronary artery disease	1.02e-06	7.67e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—APOB—coronary artery disease	1.01e-06	7.64e-06	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—NOS3—coronary artery disease	1.01e-06	7.62e-06	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—NOS3—coronary artery disease	1.01e-06	7.6e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ALB—coronary artery disease	9.96e-07	7.51e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GSTM1—coronary artery disease	9.86e-07	7.43e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—coronary artery disease	9.85e-07	7.43e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—AGT—coronary artery disease	9.69e-07	7.3e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—LPL—coronary artery disease	9.67e-07	7.29e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—NOS3—coronary artery disease	9.53e-07	7.18e-06	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL6—coronary artery disease	9.49e-07	7.16e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—APOE—coronary artery disease	9.49e-07	7.16e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GPX1—coronary artery disease	9.44e-07	7.12e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—APOA1—coronary artery disease	9.38e-07	7.07e-06	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PTGS2—coronary artery disease	9.24e-07	6.97e-06	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PTGS2—coronary artery disease	9.22e-07	6.95e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CD36—coronary artery disease	9.19e-07	6.93e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PPP2CA—coronary artery disease	9.08e-07	6.84e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PPARG—coronary artery disease	9.07e-07	6.84e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL6—coronary artery disease	9.01e-07	6.79e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—coronary artery disease	8.98e-07	6.77e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—POMC—coronary artery disease	8.94e-07	6.74e-06	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—AKT1—coronary artery disease	8.76e-07	6.6e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PTGS2—coronary artery disease	8.71e-07	6.57e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—MTHFR—coronary artery disease	8.71e-07	6.57e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TGFB1—coronary artery disease	8.48e-07	6.39e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MAPK1—coronary artery disease	8.31e-07	6.27e-06	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—AKT1—coronary artery disease	8.31e-07	6.27e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—AGT—coronary artery disease	8.28e-07	6.24e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PPARG—coronary artery disease	8.27e-07	6.23e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—POMC—coronary artery disease	8.15e-07	6.15e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ALB—coronary artery disease	8.15e-07	6.15e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—APOE—coronary artery disease	8.11e-07	6.11e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—APOA1—coronary artery disease	8.02e-07	6.04e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—NOS3—coronary artery disease	7.8e-07	5.88e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—coronary artery disease	7.68e-07	5.79e-06	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PIK3CA—coronary artery disease	7.61e-07	5.74e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ALB—coronary artery disease	7.43e-07	5.6e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PIK3CA—coronary artery disease	7.21e-07	5.44e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PTGS2—coronary artery disease	7.13e-07	5.38e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—NOS3—coronary artery disease	7.11e-07	5.36e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PPARG—coronary artery disease	7.06e-07	5.33e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—POMC—coronary artery disease	6.97e-07	5.25e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PTGS2—coronary artery disease	6.5e-07	4.9e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IL6—coronary artery disease	6.39e-07	4.82e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ALB—coronary artery disease	6.35e-07	4.79e-06	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—AKT1—coronary artery disease	6.22e-07	4.69e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NOS3—coronary artery disease	6.08e-07	4.58e-06	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PIK3CA—coronary artery disease	6.04e-07	4.55e-06	CbGpPWpGaD
Thalidomide—PTGS2—Disease—AKT1—coronary artery disease	5.89e-07	4.44e-06	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PIK3CA—coronary artery disease	5.69e-07	4.29e-06	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PIK3CA—coronary artery disease	5.68e-07	4.28e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PTGS2—coronary artery disease	5.56e-07	4.19e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PIK3CA—coronary artery disease	5.36e-07	4.04e-06	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—AKT1—coronary artery disease	4.94e-07	3.72e-06	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—AKT1—coronary artery disease	4.65e-07	3.5e-06	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—AKT1—coronary artery disease	4.64e-07	3.5e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PIK3CA—coronary artery disease	4.39e-07	3.31e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—AKT1—coronary artery disease	4.38e-07	3.3e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PIK3CA—coronary artery disease	4e-07	3.02e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—AKT1—coronary artery disease	3.58e-07	2.7e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PIK3CA—coronary artery disease	3.42e-07	2.58e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—AKT1—coronary artery disease	3.27e-07	2.46e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—AKT1—coronary artery disease	2.79e-07	2.11e-06	CbGpPWpGaD
